Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420909 · ClinicalTrials.gov registry record
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
A clinical trial of Metastatic Colorectal Cancer (mCRC), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 124
- Enrollment target
- 1
- Study location
NCT05420909 is a study of Metastatic Colorectal Cancer (mCRC) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 124 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05420909, a study of Metastatic Colorectal Cancer (mCRC), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Conditions Studied
Study Locations (1)
New Jersey
- Local Institution - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2019-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05420909
The ClinicalTrials.gov registry entry for NCT05420909 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer (mCRC) appearing as the primary indexed condition, and to 0 interventions.
NCT05420909 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05420909 about?
NCT05420909 is a clinical study titled "A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)". The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
What is the current status of trial NCT05420909?
This trial is currently completed. The enrollment target is 124 participants. The study started on 2019-01-28. Estimated completion is 2019-04-01.
What conditions does trial NCT05420909 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer (mCRC).
Who is sponsoring clinical trial NCT05420909?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05420909 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer (mCRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.